AbbVie's first move for ADC funding

AbbVie is advancing plans to bring its recently acquired first-in-class antibody-drug conjugate (ADC) Elahere to Australia, with the first move being an application for a diagnostic test.

The pharma has made an application to MSAC for "immunohistochemistry testing of solid tumour tissue to determine folate receptor alpha expression status in adults with platinum-resistant ovarian cancer, for access to PBS Elahere".

AbbVie is seeking MBS listing of a test to measure folate receptor alpha levels in ovarian cancer tumours, to determine whether they're eligible for Elahere, which is a treatment targeted towards this protein.